Nystatin for gut candida: uses, dosing and honest limits

Nystatin is an antifungal that, almost uniquely, stays where you swallow it: it is barely absorbed from the gut, so it acts locally in the gut lumen and has very little effect on the rest of the body. That makes it the natural candidate when the target is yeast inside the bowel. In the UK its licensed dosing is framed around oral candidiasis (100,000 units four times daily), while the higher “intestinal” regimens you’ll see online come from older tablet formulations no longer routinely available here - so any use for “gut candida” is off-label and should be dosed and supervised by a clinician.

How nystatin works - and why it stays in the gut

Nystatin is a polyene antifungal. It binds to ergosterol, a building block of the fungal cell membrane that human cells lack, and punches pores in that membrane so the cell’s contents leak out and it dies.⁴ Because it targets a fungal-specific molecule, it is selective for yeast over your own cells.

The feature that defines its role, though, is pharmacokinetic: nystatin is not meaningfully absorbed from an intact gut. Swallow it and it travels the length of the bowel and leaves in the stool, with negligible amounts entering the bloodstream.¹ That is a double-edged property. On one hand it means very low systemic toxicity and essentially no drug interactions. On the other, it means nystatin only works on yeast it physically contacts inside the gut - it does nothing for candida elsewhere in the body. For a problem confined to the bowel, that is exactly what you want; for systemic disease, it is the wrong tool.

Licensed UK uses and available forms

This is where UK reality has shifted, and a lot of online guidance is out of date:

• The familiar branded Nystan oral suspension has been discontinued in the UK; a generic nystatin 100,000 units/mL oral suspension remains licensed and available.¹²
• Nystatin pastilles were discontinued years ago, and 500,000-unit tablets are not a routine current UK form (they exist in some other countries).³
• The oral suspension is licensed for candidal infection of the mouth, oesophagus and intestinal tract - so an intestinal indication does formally exist on the product information, even though current prescribing dosing is written around oral candidiasis.¹

The practical upshot: in the UK today, nystatin essentially means the oral suspension, swallowed.

Dosing: licensed vs the “gut” figures online

So when a protocol online quotes “500,000 units four times a day for gut candida,” it is reaching back to a tablet dose that isn’t a standard UK product anymore, and applying it to a use that isn’t licensed. That doesn’t make it automatically wrong - but it does mean the number has weaker footing than it appears, and it should be set by a clinician who can choose an appropriate preparation and duration.

Off-label use for SIFO and gut candida

The most defensible reason to use nystatin in the gut beyond thrush is small intestinal fungal overgrowth (SIFO) - fungal overgrowth in the small bowel, confirmed where possible by aspirate, which was found in roughly a quarter of people with unexplained gut symptoms in small studies.⁶ Even there, the honest position is that a short antifungal course may improve symptoms but the evidence for reliable eradication is limited. For a contested “gut candida overgrowth” in otherwise well people, the evidence base is weaker still.

Functional-medicine protocols often extend nystatin to higher doses and longer durations, sometimes alternating it with azoles or pairing it with “biofilm disruptors” and herbal antifungals. Be clear-eyed that these are expert-opinion approaches without robust trial support - reasonable to discuss with a knowledgeable clinician, not something to assemble yourself from forum posts. The wider treatment context is in the candida pillar, and fungal overgrowth frequently overlaps with bacterial overgrowth, so the SIBO guide is worth reading alongside it.

“Die-off” versus a reaction that means stop

Many people are warned to expect a “die-off” or Herxheimer-like reaction - a brief worsening of symptoms as treatment begins, attributed to dying yeast releasing inflammatory products. It’s worth knowing that this concept is well established for some bacterial infections but rests on very thin evidence for yeast specifically.⁸ Whatever the mechanism, the practical rule is what matters, and it is non-negotiable.

Biofilms and combination ideas

One reason yeast can be hard to clear is the biofilm - a protective matrix that shields Candida from antifungals. This is the rationale behind interest in pairing nystatin with a “biofilm disruptor” such as OligoG, which made nystatin more potent against Candida in a 2023 laboratory study. As covered in detail in the OligoG research note, that finding is in-vitro only, the dramatic “32-fold” figure came from a single strain, and there are no human trials - so it’s a mechanism to watch, not a combination to adopt.

Safety, interactions and fluconazole compared

Nystatin’s safety profile is reassuring precisely because it stays in the gut. It has no significant known drug interactions, and it is considered an unlikely cause of liver injury even with prolonged use.¹⁴ Its common side effects are local and gastrointestinal - nausea, an upset stomach, occasionally diarrhoea - with hypersensitivity reactions being the uncommon-but-important exception noted above.

Contrast this with fluconazole, the systemic azole antifungal often considered for candida. Fluconazole is well absorbed and works throughout the body, which makes it powerful for systemic or oesophageal disease - but it also inhibits liver enzymes that process many other medicines, carries real interaction and QT-prolongation cautions, and warrants liver-function awareness.⁵ The choice between them is really a choice about location: nystatin for a problem confined to the gut lumen, fluconazole when the fungus is somewhere the bloodstream needs to reach.

This article is educational and does not constitute medical advice, diagnosis, or a treatment recommendation. Medication uses described as “off-label” are not licensed for that purpose in the UK and should only be considered under qualified clinical supervision. Always speak to your GP, pharmacist, or a registered specialist before starting, stopping, or changing any treatment. If you have severe or alarm symptoms - unintentional weight loss, blood in your stool, difficulty swallowing, persistent vomiting, a fever, or severe pain - seek urgent medical care.